Abstracts Archive - Page 2105 of 2425 - ACR Meeting Abstracts

Abstract Number: 2199 • 2013 ACR/ARHP Annual Meeting
Analysis Of The MHC Region In a Large Cohort Of Juvenile Idiopathic Arthritis Cases Identifies Independent Effects At HLA-DRB1
Anne Hinks¹, Joanna Cobb¹, Buhm Han^2,3, Miranda C. Marion⁴, Marc Sudman⁵, Paul Martin¹, John F. Bohnsack⁶, Lucy R. Wedderburn⁷, Johannes Peter Haas⁸, Paul de Bakker², Carl D. Langefeld⁹, Soumya Raychaudhuri², Sampath Prahalad¹⁰, Susan D. Thompson¹¹ and Wendy Thomson¹, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, ⁴Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁵Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatriacs, University of Utah, Salt Lake City, UT, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁸German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁹Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common arthritic disease of childhood and is caused by a combination of genes and environment. In the…
Abstract Number: 2200 • 2013 ACR/ARHP Annual Meeting
Fatty Acid Profiling In Juvenile Idiopathic Arthritis: The Balance Between Pro-Inflammatory and Pro-Resolving Prostanoids
Weng Tarng Cham¹, Enzo Ranieri², Janice Fletcher² and Christina A. Boros³, ¹Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, ²Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, ³Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia
Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) and are involved in all aspects of…
Abstract Number: 2201 • 2013 ACR/ARHP Annual Meeting
Exon and miRNA Arrays Reveal Complexity and Specificity Of The Juvenile Idiopathic Arthritis Neutrophil Transcriptome
Zihua Hu¹, Kaiyu Jiang², Mark B. Frank³, Yanmin Chen² and James N. Jarvis², ¹Center for Computational Research, University at Buffalo, Buffalo, NY, ²Pediatrics, The University at Buffalo, Buffalo, NY, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Data from the NIH Roadmap Epigenomics and ENCODE projects have revealed unexpected richness in mammalian transcriptomes. Large regions the genome that do not encode…
Abstract Number: 2202 • 2013 ACR/ARHP Annual Meeting
TNF-α Is Associated With Cognitive Impairment In Childhood-Onset Systemic Lupus Erythematosus
Mariana Postal¹, Nailu A. Sinicato¹, Aline T. Lapa¹, Karina Peliçari¹, Bruna Bellini¹, Paula T Fernandes², Roberto Marini³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculty of Physical Education, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Cognitive impairment is common in over 50% of SLE patients with active neurological and psychiatric disorders. Cytokine dysregulation and inﬂammation are mechanisms that may…
Abstract Number: 2203 • 2013 ACR/ARHP Annual Meeting
DEK’s Autoantigenicity In Juvenile Idiopathic Arthritis Resides In Its C-Terminal 25 Amino Acids
Barbara S. Adams¹, Miguel Rivas¹, Yuanfan Ye¹, Lili Zhao², Maureen Legendre³ and Nirit Mor-Vaknin³, ¹University of Michigan, Ann Arbor, MI, ²Department of Statistic, University of Michigan, Ann Arbor, MI, ³Internal Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: The nuclear oncoprotein DEK is a known autoantigen associated with juvenile idiopathic arthritis (JIA) and other autoimmune diseases. DEK is actively secreted by human…
Abstract Number: 2204 • 2013 ACR/ARHP Annual Meeting
Early Treatment With Methotrexate Is Associated With Extensive Re-Ordering Of The Neutrophil Transcriptome In Juvenile Idiopathic Arthritis
Zihua Hu¹, Kaiyu Jiang², Mark B. Frank³, Yanmin Chen² and James N. Jarvis², ¹Center for Computational Research, University at Buffalo, Buffalo, NY, ²Pediatrics, The University at Buffalo, Buffalo, NY, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: We have previously demonstrated a role for neutrophils in polyarticulartar juvenile idiopathic arthritis (JIA) disease pathogenesis. For example, JIA neutrophils show specific abnormalities in…
Abstract Number: 2205 • 2013 ACR/ARHP Annual Meeting
Galectin-3 and Transforming Growth Factor-β Signaling In The Pathogenesis Of Coronary Artery Aneurysms In Kawasaki Disease
Fujito Numano¹, Matthew Vejar², Chisato Shimizu¹, Susan Jimenez-Fernandez¹, Adriana H. Tremoulet³, Jane C. Burns¹ and Lori B. Daniels², ¹Pediatrics, UC San Diego, School of Medicine, La Jolla, CA, ²Departments of Medicine, UC San Diego, School of Medicine, La Jolla, CA, ³Department of Pediatrics, UC San Diego, School of Medicine, La Jolla, CA
Background/Purpose: Kawasaki disease (KD) is a self-limited acute vasculitis of young children, and coronary artery aneurysms (CAA) are the most significant complication. Despite appropriate treatment…
Abstract Number: 2206 • 2013 ACR/ARHP Annual Meeting
Detection Of State-Specific RNA Transcripts In Juvenile Idiopathic Arthritis Neutrophils Using RNA Sequencing
Kaiyu Jiang¹, Xiaoyun Sun², Yanmin Chen¹, Yufeng Shen² and James N. Jarvis¹, ¹Pediatrics, The University at Buffalo, Buffalo, NY, ²Center for Computational Biology & Bioinformatics, Columbia University, New York, NY
Background/Purpose: Once considered non-functional, the vast regions of the human genome that do not contain protein-coding genes are now known to contain important regulatory elements. …
Abstract Number: 2207 • 2013 ACR/ARHP Annual Meeting
Plasma Cytokine Concentrations Are Associated With Folate Perturbations and Methotrexate Polyglutamate Accumulation In The Peripheral Blood Of Juvenile Idiopathic Arthritis Patients Treated With Low-Dose Methotrexate
Ryan S. Funk¹, Leon van Haandel¹, Marcia Chan², Lanny J. Rosenwasser², Andrew Lasky³, Maria F. Ibarra⁴, Mark F. Hoeltzel⁵, J.S. Leeder¹ and Mara L Becker⁶, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Pediatric Immunology Research, Children's Mercy Hospital, Kansas City, MO, ³Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, ⁶Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Methotrexate inhibits the production of inflammatory cytokines, but is also an antifolate. The activity of MTX is thought to depend on the formation of…
Abstract Number: 2208 • 2013 ACR/ARHP Annual Meeting
Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Yuki Osako¹, Yukiko Nonaka², Harumi Akaike², Tomohiro Kubota³, Tsuyoshi Yamatou², Tomokazu Nagakura⁴, Junko Yasumura⁵, Hiroyuki Imanaka² and Syuji Takei⁶, ¹School of Health Sciences, Faculty of Medicine,Department of Maternal & Child Nursing and Midwifery, Kagoshima University, Kagoshima city, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Biologic agents, newly developed medications targeting for inflammatory cytokines such as TNF-alpha or IL-6, have been drastically improving the disease course of JIA who…
Abstract Number: 2209 • 2013 ACR/ARHP Annual Meeting
Transition From The Pediatric Rheumatologist To The Adult Rheumatologist: Outcomes Of 5 Years Of Experience Between Two Institutions
Elizabeth C. Ortiz¹, Agarwal Arunima², Sandra Mintz³ and Bracha Shaham⁴, ¹Rheumatology, University of Southern California, Los Angeles, CA, ²Division of Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA, ³4650 Sunset Boulevard, Mailstop 60, Children's Hospital of LA, Los Angeles, CA, ⁴Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: It is well documented that children with rheumatologic conditions are living into adulthood and require transition of care into the adult medical center. This…
Abstract Number: 2176 • 2013 ACR/ARHP Annual Meeting
Relationships Between Physician and Patient Scored Clinical Outcome Measures In Pediatric Localized Scleroderma
Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissue leading to sclerosis and complications such as joint contractures. The…
Abstract Number: 2170 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Long-Term Rituximab Use In Patients With Systemic Juvenile Idiopathic Arthritis: The Results Of 5-Year Follow-Up In Real Clinical Practice
Ekaterina Alexeeva^1,2, Alexander Baranov^2,3, Saniya Valieva¹, Tatyana Bzarova¹, Rina Denisova¹, Kseniya Isayeva¹, Tatyana Sleptsova¹, Elena Mitenko¹, Evgeniya Chistyakova^1,2, Anna Fetisova¹, Elena Semikina⁴ and Svetlana Akulova¹, ¹Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁴Clinical Laboratory, Scientific Center of Children's Health of RAMS, Moscw, Russia
Background/Purpose: To assess the efficacy and safety of rituximab (RT) treatment in long-term follow-up of children with systemic juvenile idiopathic arthritis (sJIA). Methods: The results…
Abstract Number: 2171 • 2013 ACR/ARHP Annual Meeting
Identification Of Best Cutoff Points and Clinical Signs Specific For Early Recognition Of Macrophage Activation Syndrome In Active Systemic Juvenile Idiopathic Arthritis
Mikhail Kostik¹, Margarita Dubko², Ludmila Snegireva¹, Vera Masalova¹, Tatyana Kornishina², Natalya Abramova³, Irina Chikova², Natalya Glebova³, Ekaterina Kuchinskaya³, Eugenia Balbotkina³, Olga Kalshnikova³ and Vyacheslav Chasnyk⁴, ¹Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ²State Pediatric Medical University, Saint-Petersburg, Russia, ³Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ⁴Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia
Background/Purpose: Macrophage activation syndrome (MAS) – is a severe life-threatening hematological condition, mostly complicated systemic juvenile idiopathic arthritis (SJIA). Early detection of MAS can lead…
Abstract Number: 2172 • 2013 ACR/ARHP Annual Meeting
Single MVK Mutation and Recurrent Fevers
Karyl Barron¹, Amanda K. Ombrello², Donald P. Goldsmith³, Ivona Aksentijevich², Anne Jones² and Daniel L. Kastner², ¹Div Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, ²Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA
Background/Purpose: HyperIgD syndrome is an autoinflammatory disorder caused by mutations in the MVK gene. While mutations in most patients follow autosomal recessive inheritance, we have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].